Convelo Therapeutics develops remyelination-enhancing therapies that target the central nervous system's myelination pathway to regenerate myelin around nerve cells. This approach aims to restore neurological function in patients with multiple sclerosis, moving beyond mere symptom management to promote active repair and revitalization.
Funding
$20.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Multiple sclerosis (MS) and other neurological disorders damage myelin, disrupting nerve cell communication and leading to impaired neurological function. Current treatments primarily focus on managing symptoms rather than repairing the damaged myelin sheath. A therapeutic approach that actively promotes remyelination is needed to restore neurological function and improve patient outcomes.
Solution
Convelo Therapeutics is developing remyelination-enhancing therapies designed to target the central nervous system's myelination pathway and stimulate myelin regeneration around nerve cells. Their drug discovery platform identifies novel therapeutics that promote the formation of new oligodendrocytes, the cells responsible for myelin production. By enhancing the body's natural repair mechanisms, Convelo aims to restore efficient nerve signal transmission and improve neurological function in patients with MS and other demyelinating diseases. This approach offers the potential for active repair and revitalization, moving beyond traditional symptom management to address the underlying cause of neurological deficits.
Target Audience
The primary target audience includes individuals with multiple sclerosis and other demyelinating neurological disorders, as well as clinicians and researchers focused on developing new treatments for these conditions.
Features
- Proprietary drug discovery platform targeting the myelination pathway in the central nervous system
- Focus on developing therapeutics that enhance oligodendrocyte formation and myelin regeneration
- High-efficiency remyelination technology to accelerate the drug discovery process
- Aims to restore neurological function by repairing damaged myelin sheaths